公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases | CHIH-HSIN YANG ; Schuler M.; Popat S.; Miura S.; Heeke S.; Park K.; Märten A.; Kim E.S. | Journal of Thoracic Oncology | 175 | 156 | |
2014 | Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis | Popat S; Mok T; CHIH-HSIN YANG ; Wu Y.-L; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L. | Lung Cancer | 46 | 44 | |
2019 | Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations | SHENG-KAI LIANG ; JEN-CHUNG KO ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Lung Cancer | 25 | 25 | |
2015 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials | CHIH-HSIN YANG ; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. | The Lancet Oncology | 1318 | 1236 | |
2016 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial | Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG ; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. | The Lancet Oncology | 905 | 827 | |
2017 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial | Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG ; Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K. | Annals of Oncology | 424 | 369 | |
2012 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial | Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG | The Lancet Oncology | 879 | 785 | |
2013 | ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors | Huang C.-P.; Tsai M.-F.; Chang T.-H.; Tang W.-C.; Chen S.-Y.; Lai H.-H.; Lin T.-Y.; CHIH-HSIN YANG ; PAN-CHYR YANG ; JIN-YUAN SHIH ; Lin S.-B. | Cancer Letters | 115 | 109 | |
2016 | Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: A phase II global study | Ou S.-H.I; Ahn J.S; De Petris L; Govindan R; CHIH-HSIN YANG ; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez S.V; Mekhail T; Spira A; Bordogna W; Balas B; Morcos P.N; Monnet A; Zeaiter A; Kim D.-W. | Journal of Clinical Oncology | 541 | 490 | |
2021 | Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study | Park K.; Haura E.B.; Leighl N.B.; Mitchell P.; Shu C.A.; Girard N.; Viteri S.; Han J.-Y.; Kim S.-W.; Lee C.K.; Sabari J.K.; Spira A.I.; Yang T.-Y.; Kim D.-W.; Lee K.H.; Sanborn R.E.; Trigo J.; Goto K.; Lee J.-S.; CHIH-HSIN YANG ; Govindan R.; Bauml J.M.; Garrido P.; Krebs M.G.; Reckamp K.L.; Xie J.; Curtin J.C.; Haddish-Berhane N.; Roshak A.; Millington D.; Lorenzini P.; Thayu M.; Knoblauch R.E.; Cho B.C. | Journal of Clinical Oncology | 298 | 226 | |
2023 | Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial | Chmielecki, Juliann; Mok, Tony; Wu, Yi-Long; Han, Ji-Youn; Ahn, Myung-Ju; Ramalingam, Suresh S; John, Thomas; Okamoto, Isamu; CHIH-HSIN YANG ; Shepherd, Frances A; Bulusu, Krishna C; Laus, Gianluca; Collins, Barbara; Barrett, J Carl; Hartmaier, Ryan J; Papadimitrakopoulou, Vassiliki | Nature communications | 21 | 16 | |
2016 | Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review | YEN-TING LIN ; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Clinical Lung Cancer | 26 | 23 | |
2007 | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | CHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG | Investigational New Drugs | 104 | 103 | |
1999 | Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells | CHIH-HSIN YANG ; Kuo M.-L.; Chen J.-C.; YAO-CHANG CHEN | British Journal of Cancer | 134 | 122 | |
2000 | Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: An useful salvage therapy | SHANG-YI HUANG ; CHIH-HSIN YANG ; YAO-CHANG CHEN | Leukemia and Lymphoma | 34 | 34 | |
2008 | Arsenite-induced cytotoxicity in dorsal root ganglion explants | Chou Y.H; Chao P.L; Tsai M.J; Cheng H.H; Chen K.B; Yang D.M; CHIH-HSIN YANG ; Lin A.M.Y. | Free Radical Biology and Medicine | 17 | 14 | |
2022 | Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations | Ahn, Myung-Ju; Mendoza, Marvin Jonne L; Pavlakis, Nick; Kato, Terufumi; Soo, Ross A; Kim, Dong-Wan; Liam, Chong Kin; Hsia, Te-Chun; Lee, Chee Khoon; Reungwetwattana, Thanyanan; Geater, Sarayut; Chan, Oscar Siu Hong; Prasongsook, Naiyarat; Solomon, Benjamin J; Nguyen, Thi Thai Hoa; Kozuki, Toshiyuki; CHIH-HSIN YANG ; Wu, Yi-Long; Mok, Tony Shu Kam; Tan, Daniel Shao-Weng; Yatabe, Yasushi | Clinical lung cancer | 7 | 3 | |
2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Tan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. | Journal of Thoracic Oncology | 32 | 30 | |
2016 | Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer | Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG ; Barrett J.C; Jänne P.A. | Journal of Clinical Oncology | 697 | 633 | |
2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 55 | 49 | |